ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sarepta Acquires Manufacturing Site

by Lisa M. Jarvis
June 2, 2014 | APPEARED IN VOLUME 92, ISSUE 22

Anticipating approval next year of eteplirsen, an RNA-based treatment for Duchenne muscular dystrophy, Sarepta Therapeutics will spend $25 million to acquire and upgrade a former Eisai drug manufacturing facility in Andover, Mass. Sarepta says the Japanese firm built the site in 1996 and upgraded it in 2006. It supports 40 technicians and other staffers when fully operational. In April, Sarepta said it will file a New Drug Application for eteplirsen by the end of this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment